Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues

Proteomics

Volumn 14, Issue 7-8, 2014, Pages 956-964

  Casadonte, Rita ^a   Kriegsmann, Mark ^b   Zweynert, Friederike ^c   Friedrich, Katrin ^d   Bretton, Gustavo ^d   Otto, Mike ^a,c,e   Deininger, Sören Oliver ^f   Paape, Rainer ^f   Belau, Eckhard ^f   Suckau, Detlev ^f   Aust, Daniela ^d   Pilarsky, Christian ^d   Kriegsmann, Jörg ^a,c,e  

^a PROTEOPATH GMBH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute of Molecular Pathology   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Zentrum fur Histologie Zytologie und Molekulare Diagnostik   (Germany)

^f BRUKER DALTONIK GMBH   (Germany)

Author keywords

Formalin fixed paraffin embedded; Imaging MS; MALDI; Metastasis; Technology; Tumor typing

Indexed keywords

FORMALDEHYDE; PARAFFIN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; PANCREAS CANCER; PANCREAS METASTASIS; PATHOLOGIST; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SENSIBILITY; STATISTICAL MODEL; TISSUE FIXATION; TRAINING; TUMOR BIOPSY; TUMOR CLASSIFICATION; BIOSYNTHESIS; BREAST NEOPLASMS; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PATHOLOGY; PROTEOMICS; SECONDARY;

BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PARAFFIN EMBEDDING; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84897423154     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300430     Document Type: Article

References (50)

1. Pavlidis, N., Pentheroudakis, G., Cancer of unknown primary site. Lancet 2012, 379, 1428-1435.
2. Varadhachary, G. R., Spector, Y., Abbruzzese, J. L., Rosenwald, S. et al., Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin. Cancer Res. 2011, 17, 4063-4070.
3. Morawietz, L., Floore, A., Stork-Sloots, L., Folprecht, G. et al., Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Archiv. 2010, 456, 23-29.
4. Gruner, B. M., Hahne, H., Mazur, P. K., Trajkovic-Arsic, M. et al., MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PloS One 2012, 7, e39424.
5. Meding, S., Nitsche, U., Balluff, B., Elsner, M. et al., Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J. Proteome. Res. 2012, 11, 1996-2003.
6. Balluff, B., Rauser, S., Meding, S., Elsner, M. et al., MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am. J. Pathol. 2011, 179, 2720-2729.
7. Kriegsmann, M., Seeley, E. H., Schwarting, A., Kriegsmann, J. et al., MALDI MS imaging as a powerful tool for investigating synovial tissue. Scand. J. Rheumatol. 2012, 41, 305-309.
8. Scholz, B., Sköld, K., Kultima, K., Fernandez, C. et al., Impact of temperature dependent sampling procedures in proteomics and peptidomics-a characterization of the liver and pancreas post mortem degradome. Mol. Cell. Proteomics 2011, 10, M900229mcp200.
9. Skold, K., Svensson, M., Norrman, M., Sjogren, B. et al., The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2-20 and peptides as sample quality indicators. Proteomics 2007, 7, 4445-4456.
10. Groseclose, M. R., Andersson, M., Hardesty, W. M., Caprioli, R. M., Identification of proteins directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. J. Mass Spectrom. 2007, 42, 254-262.
11. Caprioli, R. M., Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res. 2005, 65, 10642-10645.
12. Rahman, S. M., Gonzalez, A. L., Li, M., Seeley, E. H. et al., Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res. 2011, 71, 3009-3017.
13. Seeley, E. H., Washington, M. K., Caprioli, R. M., M'Koma, A. E., Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin. Appl. 2013, 7, 541-549.
14. Balluff, B., Elsner, M., Kowarsch, A., Rauser, S. et al., Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J. Proteome Res. 2010, 9, 6317-6322.
15. Berezowska, S., Novotny, A., Bauer, K., Feuchtinger, A. et al., Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PloS One 2013, 8, e69098.
16. Zhang, K., Yuan, K., Wu, H., Li, Q. et al., Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS. Appl. Biochem. Biotechnol. 2012, 166, 753-763.
17. Qian, J., Li, F., Yu, J., Yang, Z., Chen, J., Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics. Hepatogastroenterology 2011, 58, 1828-1833.
18. Lee, D. H., Chung, K., Song, J. A., Kim, T. H. et al., Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J. Proteome Res. 2010, 9, 5668-5676.
19. Elsner, M., Rauser, S., Maier, S., Schone, C. et al., MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J. Proteomics 2012, 75, 4693-4704.
20. Meding, S., Balluff, B., Elsner, M., Schone, C. et al., Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J. Pathol. 2012, 228, 459-470.
21. Nipp, M., Elsner, M., Balluff, B., Meding, S. et al., S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J. Mol. Med. 2012, 90, 163-174.
22. Peng, Y., Li, X., Wu, M., Yang, J. et al., New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol. Biosystems 2012, 8, 3077-3088.
23. Schone, C., Hofler, H., Walch, A., MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin. Biochem. 2013, 46, 539-545.
24. Riihimaki, M., Thomsen, H., Hemminki, A., Sundquist, K., Hemminki, K., Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 2013, 13, 36.
25. Gustafsson, J. O., Oehler, M. K., McColl, S. R., Hoffmann, P., Citric acid antigen retrieval (CAAR) for tryptic peptide imaging directly on archived formalin-fixed paraffin-embedded tissue. J. Proteome. Res. 2010, 9, 4315-4328.
26. Casadonte, R., Caprioli, R. M., Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat. Protocols 2011, 6, 1695-1709.
27. Schwamborn, K., Krieg, R. C., Reska, M., Jakse, G. et al., Identifying prostate carcinoma by MALDI-Imaging. Int. J. Mol. Med. 2007, 20, 155-159.
28. Norris, J. L., Cornett, D. S., Mobley, J. A., Andersson, M. et al., Processing MALDI mass spectra to improve mass spectral direct tissue analysis. Int. J. Mass Spectrom. 2007, 260, 212-221.
29. Suckau, D., Resemann, A., Schuerenberg, M., Hufnagel, P. et al., A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. Anal. Bioanal. Chem. 2003, 376, 952-965.
30. Holle, A., Haase, A., Kayser, M., Hohndorf, J., Optimizing UV laser focus profiles for improved MALDI performance. J. Mass Spectrom. 2006, 41, 705-716.
31. Pentheroudakis, G., Golfinopoulos, V., Pavlidis, N., Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer 2007, 43, 2026-2036.
32. Lewis, G. H., Subhawong, A. P., Nassar, H., Vang, R. et al., Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am. J. Clin. Pathol. 2011, 135, 587-591.
33. Luo, M. H., Huang, Y. H., Ni, Y. B., Tsang, J. Y. et al., Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Hum. Pathol. 2013, 44, 1241-1250.
34. Chia, S. Y., Thike, A. A., Cheok, P. Y., Tan, P. H., Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast 2010, 19, 355-359.
35. Han, L., Pansare, V., Al-Abbadi, M., Husain, M., Feng, J., Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn. Cytopathol. 2010, 38, 333-336.
36. Greco, F. A., Spigel, D. R., Yardley, D. A., Erlander, M. G. et al., Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010, 15, 500-506.
37. Monzon, F. A., Medeiros, F., Lyons-Weiler, M., Henner, W. D., Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn. Pathol. 2010, 5, 3.
38. Varadhachary, G., New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin. Cancer Res. 2013, 19, 4027-4033.
39. Schwamborn, K., Imaging mass spectrometry in biomarker discovery and validation. J. Proteomics 2012, 75, 4990-4998.
40. Angel, P. M., Caprioli, R. M., Matrix-assisted laser desorption ionization imaging mass spectrometry: in situ molecular mapping. Biochemistry 2013, 52, 3818-3828.
41. O'Neill, P. A., Shaaban, A. M., West, C. R., Dodson, A. et al., Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br. J. Cancer 2004, 90, 182-188.
42. Mlynarczyk-Liszka, J., Maksymiuk, B., Ponikiewska, D., Krzyzowska-Gruca, S. et al., HSP27 diagnostic utility in the fine needle aspirate of breast. Correlation with progesterone and estrogen receptors. Neoplasma 2009, 56, 357-360.
43. Zhou, J., Allred, D. C., Avis, I., Martinez, A. et al., Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res. Treatment 2001, 66, 217-224.
44. Tian, H. M., Liu, X. H., Han, W., Zhao, L. L. et al., Differential expression of filamin A and its clinical significance in breast cancer. Oncol. Lett. 2013, 6, 681-686.
45. Thalappilly, S., Suliman, M., Gayet, O., Soubeyran, P. et al., Identification of multi-SH3 domain-containing protein interactome in pancreatic cancer: a yeast two-hybrid approach. Proteomics 2008, 8, 3071-3081.
46. Groseclose, M. R., Massion, P. P., Chaurand, P., Caprioli, R. M., High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008, 8, 3715-3724.
47. Lazova, R., Seeley, E. H., Keenan, M., Gueorguieva, R., Caprioli, R. M., Imaging mass spectrometry-a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am. J. Dermatopathol. 2012, 34, 82-90.
48. Oezdemir, R. F., Gaisa, N. T., Lindemann-Docter, K., Gostek, S. et al., Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasia. Clin. Biochem. 2012, 45, 7-11.
49. Hardesty, W. M., Kelley, M. C., Mi, D., Low, R. L., Caprioli, R. M., Protein signatures for survival and recurrence in metastatic melanoma. J. Proteomics 2011, 74, 1002-1014.
50. Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P. et al., Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003, 362, 433-439.